Published on 22 Mar 2024 on GuruFocus.com via Yahoo Finance
Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT), a biotechnology company focused on the discovery, development, and commercialization of RNA therapeutics for rare diseases and vaccines, has reported an insider sale according to a recent SEC filing. Chief Scientific Officer & Chief Operating Officer Pad Chivukula disposed of 8,565 shares of the company on March 19, 2024.Pad Chivukulas transaction was executed at an average price of $35.01 per share, resulting in a total sale amount of $299,785.65. Following this transaction, the insider's direct ownership in Arcturus Therapeutics Holdings Inc stands adjusted as per the latest filings.Over the past year, Pad Chivukula has engaged in multiple transactions, selling a cumulative total of 93,565 shares and making no purchases of the company's stock.The insider transaction history for Arcturus Therapeutics Holdings Inc shows a pattern of sales by insiders over the past year, with 12 recorded sells and no insider buys during the same period.
Arcturus Therapeutics Holdings Inc's Chief Scientific Officer & COO Pad Chivukula Sells 8,565 Shares
On the valuation front, Arcturus Therapeutics Holdings Inc's shares were trading at $35.01 on the date of the insider's recent sale, giving the company a market capitalization of approximately $891.164 million.The stock's price-to-GF-Value ratio stands at 0.31, with a GuruFocus Value of $111.56, indicating that Arcturus Therapeutics Holdings Inc is currently categorized as a Possible Value Trap, Think Twice according to the GF Value metric.